Want to see TTRX full AI Analyst Report?
TTRX Stock Chart & Stats
$9.84
--
Market closed
$9.84
--
Day’s Range― - ―
52-Week Range$2.57 - $26.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)136.46K
Market Cap
$396.48M
Enterprise Value$213.29
Total Cash (Recent Filing)$10.29M
Total Debt (Recent Filing)$6.12M
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Nov 12, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding29,788,040
10 Day Avg. Volume202,897
30 Day Avg. Volume136,461
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)11.55
Price to Sales (P/S)0.00
P/FCF Ratio-19.94
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.00Price Target Upside52.44% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$450.00K
Bulls Say, Bears Say
Bulls Say
GX-03 Clinical ProgressGX-03 has produced encouraging interim clinical signals while the adaptive Phase 2 design broadens enrollment across disease severity groups. This supports a more targeted development strategy and could improve the program’s commercial relevance if later data confirm efficacy and safety.
Pipeline And Platform PotentialThe company is building a multi-indication development strategy around GX-03 and its PermaFusion delivery platform rather than relying on a single trial opportunity. Planned studies across dermatology and cited patent protection provide potential for broader, durable product value.
Low Leverage And Recapitalized Balance SheetVery low debt reduces fixed financial obligations and leaves the company less exposed to leverage-related stress. The sharp increase in assets and return to positive equity also provide a stronger capital foundation for continuing development, although sustaining it depends on managing cash use.
Bears Say
Pre-Revenue Loss-Making ModelTurn Therapeutics has not yet demonstrated commercial revenue to offset operating expenses, and the material deterioration in 2025 EBIT indicates rising costs without corresponding business progress. Until a product reaches the market, earnings visibility remains limited and financial performance depends on development execution.
Accelerating Cash BurnPersistent negative operating and free cash flow means the company cannot currently fund development from internally generated cash. The larger 2025 outflows increase reliance on external financing and make the path to sustained operations more sensitive to clinical spending, timing, and funding availability.
Equity Dilution And Financing DependenceThe cashless warrant exercise increased the share count without providing new funds, directly affecting existing ownership while highlighting the company’s use of structured equity financing. Continued reliance on such instruments could dilute shareholders further as Turn funds operations before revenue emerges.
Turn Therapeutics Inc News
TTRX FAQ
What was Turn Therapeutics Inc’s price range in the past 12 months?
Turn Therapeutics Inc lowest stock price was $2.57 and its highest was $26.50 in the past 12 months.
What is Turn Therapeutics Inc’s market cap?
Turn Therapeutics Inc’s market cap is $396.48M.
When is Turn Therapeutics Inc’s upcoming earnings report date?
Turn Therapeutics Inc’s upcoming earnings report date is Nov 12, 2026 which is in 39 days.
How were Turn Therapeutics Inc’s earnings last quarter?
Turn Therapeutics Inc released its earnings results on Aug 12, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.02 by -$0.18.
Is Turn Therapeutics Inc overvalued?
According to Wall Street analysts Turn Therapeutics Inc’s price is currently Undervalued.
Does Turn Therapeutics Inc pay dividends?
Turn Therapeutics Inc does not currently pay dividends.
What is Turn Therapeutics Inc’s EPS estimate?
Turn Therapeutics Inc’s EPS estimate is -0.09.
How many shares outstanding does Turn Therapeutics Inc have?
Turn Therapeutics Inc has 29,788,040 shares outstanding.
What happened to Turn Therapeutics Inc’s price movement after its last earnings report?
Turn Therapeutics Inc reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.02. Following the earnings report the stock price went down -6.452%.
Which hedge fund is a major shareholder of Turn Therapeutics Inc?
Currently, no hedge funds are holding shares in TTRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Turn Therapeutics Inc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$15.00 (52.44% Upside)
$15.00 (52.44% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
240.67%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Turn Therapeutics Inc
Turn Therapeutics Inc., officially known as Global Health Solutions, Inc., is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes. The company utilizes a proprietary drug delivery system engineered to effectively permeate skin and nail tissues. This advanced technology is integrated into their solutions for both acute and chronic wound care, specifically designed to help combat antibiotic resistance. Consequently, these products empower healthcare institutions to effectively manage a broad spectrum of dermatological challenges, encompassing everything from sudden injuries and persistent wounds to general skin ailments and specific dermatoses. Global Health Solutions, Inc. was established in 2015 and maintains its headquarters in Westlake Village, California.
TTRX Stock 12 Month Forecast
Average Price Target
$15.00
▲(52.44% Upside)
Technical Analysis
AIM ImmunoTech
―
Scinai Immunotherapeutics
―
Pulmatrix
―
Dermata Therapeutics
―
Azitra Inc
―
Ownership Overview
59.05% Insiders
0.23% Mutual Funds
0.71% Other Institutional Investors
39.91% Public Companies and
Individual Investors